Do You Need New Labs Every Refill? A GLP-1 Monitoring Requirements Guide
The baseline labs to have before starting, the actual ongoing monitoring schedule used by responsible prescribers, and when more frequent monitoring is clinically warranted.
One of the most common questions from GLP-1 patients: do I need new labs every time I refill? The answer depends on which medication, what dose, how long you've been on it, and your individual health profile. Here's the actual monitoring framework used by clinicians.
Baseline labs before starting
Standard baseline workup before GLP-1 initiation
- Hemoglobin A1C — establishes diabetes status, affects dosing and monitoring
- Comprehensive metabolic panel — baseline kidney and liver function
- Lipid panel — GLP-1 medications improve lipid profiles; baseline establishes change
- Thyroid panel (TSH) — personal/family history of MTC is a contraindication; baseline TSH useful
- CBC — optional but establishes baseline for patients with anemia or inflammatory conditions
- Pregnancy test — for women of childbearing potential
Ongoing monitoring — what's actually required at refills
After the first 3–6 months, monitoring requirements drop significantly for patients without complications or metabolic disease:
| Timepoint | Labs typically warranted |
|---|---|
| Month 3 | A1C (if diabetic), CMP if kidney disease concern, weight check |
| Month 6 | A1C (all patients), CMP, lipid panel |
| Month 12 | Full panel: A1C, CMP, CBC, lipid panel, TSH |
| Annual ongoing | A1C, CMP, lipid panel minimum |
Most platforms don't require full labs at every refill for stable patients. What they do require: documented check-in (weight, side effects, adherence) and periodic labs per schedule above. Platforms requiring full labs at every 1–3 month refill for a patient with no comorbidities may be over-medicalizing — or generating lab revenue. Standard of care is periodic, not constant.
When more monitoring is warranted
More frequent labs make sense if you have: type 2 diabetes (A1C every 3 months initially), chronic kidney disease (CMP every 3 months), history of pancreatitis (amylase/lipase at any new symptom), or significant medication changes affecting metabolic parameters.
Verified telehealth providers
Monitoring-inclusive program — labs managed through the platform.
Paid link Get started →Structured monitoring protocol built into program — not a surprise expense.
Paid link Get started →